Hidehito Horinouchi summarizes some abstracts of WCLC24
Hidehito Horinouchi shared on X:
Antibody Drug Conjugates in SCLC by Charlie Rudin
- Ifinatamab Deruxtecan (I-DXd) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Ideate-lung01
Redefining First-Line EGFR Therapy by Anwen Xiong
- Phase III Study of Rilertinib vs Gefitinib as 1st-Line Pts with Locally Advanced or Metastatic EGFR-m NSCLC
Perioperative Strategies 1 by Enriqueta Felip
- IMpower010 5-y Subgroup Analysis and Relapse Patterns: Phase 3 Study of Atezolizumab vs BSC in Stage II-IIIA NSCLC
Perioperative Strategies 1 by Jones David R.
- Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Periope Pembro for Early-Stage NSCLC
Presidential 2 by Xiuning Le
- FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations
Presidential 2 by J. Yang
- Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial
Presidential 1 by Annette McWilliams
- Triaging ILST Screening Participants at Program Entry: Comparative Performance of PanCan versus LungRADSv1.1
Presidential 1 by Marina Garassino
- Normalized Membrane Ratio of TROP2 by Quantitative Continuous Scoring is predictive of Outcomes in TROPION-Lung 01
Find more abstract summaries by Hidehito Horinouchi on Hidehito Horinouchi/X
Hidehito Horinouchi is the Assistant Chief of the National Cancer Center Hospital. He also serves as the Secretary General of the Lung Cancer Study Group, Japan Clinical Oncology Group, and the Deputy Chief of the Center for Education and Professional Career Development at the National Cancer Center Hospital. He specializes in multimodal treatment strategies, including medical, surgical, and radiation oncology, for patients with thoracic malignancies.